These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3204620)

  • 1. Research challenges: overview of epidemiological study designs.
    Bombardier C
    J Rheumatol Suppl; 1988 Oct; 17():5-8. PubMed ID: 3204620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodologic challenges to studying patient safety and comparative effectiveness.
    Strom BL
    Med Care; 2007 Oct; 45(10 Supl 2):S13-5. PubMed ID: 17909371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of different logistical approaches to postmarketing surveillance.
    Strom BL
    J Rheumatol Suppl; 1988 Oct; 17():9-13. PubMed ID: 3204621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ethical issues of the postmarketing surveillance of drug teratogenicity in Hungary.
    Czeizel AE
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):635-9. PubMed ID: 11980253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When should case-only designs be used for safety monitoring of medical products?
    Maclure M; Fireman B; Nelson JC; Hua W; Shoaibi A; Paredes A; Madigan D
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():50-61. PubMed ID: 22262593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research.
    Madigan D; Ryan P
    Epidemiology; 2011 Sep; 22(5):629-31. PubMed ID: 21811110
    [No Abstract]   [Full Text] [Related]  

  • 10. Case-control studies.
    Hochberg MC
    J Rheumatol Suppl; 1983 Nov; 10():92-5. PubMed ID: 6607352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Approach to epidemiological cohort designs].
    Morales González JM
    Neurologia; 2004 Sep; 19 Suppl 1():23-30. PubMed ID: 15372332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An algorithm for the design of epidemiologic studies applied to drug surveillance.
    Figueiras A; Tato F; Takkouche B; Gestal-Otero JJ
    Eur J Clin Pharmacol; 1997; 51(6):445-8. PubMed ID: 9112057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of health care databases in pharmacoepidemiology.
    Hennessy S
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):311-3. PubMed ID: 16611207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological study designs.
    Diomidus M
    Stud Health Technol Inform; 2002; 65():126-35. PubMed ID: 15460223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmarketing surveillance for human teratogenicity: a model approach.
    Chambers CD; Braddock SR; Briggs GG; Einarson A; Johnson YR; Miller RK; Polifka JE; Robinson LK; Stepanuk K; Lyons Jones K
    Teratology; 2001 Nov; 64(5):252-61. PubMed ID: 11745831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proposal of guidelines for the set-up of pharmaco-epidemiologic studies in drug surveillance].
    de Tricornot B; Saddier P; Bons B; Clément JP; Courtand M; Lamarque V; Thomas A; Tomczyk S; Vaissère J
    Therapie; 1997; 52(6):579-85. PubMed ID: 9734111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A note on post-marketing safety study design to characterise time-dependent adverse events.
    Narukawa M; Yafune A
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1146-52. PubMed ID: 17803255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immortal time bias in pharmaco-epidemiology.
    Suissa S
    Am J Epidemiol; 2008 Feb; 167(4):492-9. PubMed ID: 18056625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different study designs in the epidemiology of cancer: case-control vs. cohort studies.
    Singh H; Mahmud SM
    Methods Mol Biol; 2009; 471():217-25. PubMed ID: 19109782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.